| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.11 | 0.006 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | -0.095 | 0.008 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.14 | 0.009 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.086 | 0.01 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | AZD-2281 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.01 |
| mRNA | ABT-888 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.01 |